MRI of the Swallow Tail Sign: A Useful Marker in the Diagnosis of Lewy Body Dementia?

References

1. 1.↵
   2. Haller S,
   3. Garibotto V,
   4. Kövari E, et al

   . Neuroimaging of dementia in 2013: what radiologists need to know. Eur Radiol 2013;23:3393–404 doi:10.1007/s00330-013-2957-0 pmid:23839168

   CrossRefPubMed
2. 2.↵
   2. McKeith I

   . Dementia with Lewy bodies. Dialogues Clin Neurosci 2004;6:333–41 pmid:22033743

   PubMed
3. 3.↵
   2. McVeigh C,
   3. Passmore P

   . Vascular dementia: prevention and treatment. Clin Interv Aging 2006;1:229–35 doi:10.2147/ciia.2006.1.3.229 pmid:18046875

   CrossRefPubMed
4. 4.↵
   2. McKeith IG,
   3. Dickson DW,
   4. Lowe J, et al

   ; Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863–72 doi:10.1212/01.wnl.0000187889.17253.b1 pmid:16237129

   Abstract/FREE Full Text
5. 5.↵
   2. Mrak RE,
   3. Griffin WS

   . Dementia with Lewy bodies: definition, diagnosis, and pathogenic relationship to Alzheimer's disease. Neuropsychiatr Dis Treat 2007;3:619–25 pmid:19300591

   PubMed
6. 6.↵
   2. Mak E,
   3. Su L,
   4. Williams GB, et al

   . Neuroimaging characteristics of dementia with Lewy bodies. Alzheimers Res Ther 2014;6:18 doi:10.1186/alzrt248 pmid:25031634

   CrossRefPubMed
7. 7.↵
   2. Brown RK,
   3. Bohnen NI,
   4. Wong KK, et al

   . Brain PET in suspected dementia: patterns of altered FDG metabolism. Radiographics 2014;34:684–701 doi:10.1148/rg.343135065 pmid:24819789

   CrossRefPubMed
8. 8.↵
   2. Binnewijzend MA,
   3. Kuijer JP,
   4. Benedictus MR, et al

   . Cerebral blood flow measured with 3D pseudocontinuous arterial spin-labeling MR imaging in Alzheimer disease and mild cognitive impairment: a marker for disease severity. Radiology 2013;267:221–30 doi:10.1148/radiol.12120928 pmid:23238159

   CrossRefPubMedWeb of Science
9. 9.↵
   2. O'Brien JT,
   3. Firbank MJ,
   4. Davison C, et al

   . 18F-FDG PET and perfusion SPECT in the diagnosis of Alzheimer and Lewy body dementias. J Nucl Med 2014;55:1959–65 doi:10.2967/jnumed.114.143347 pmid:25453043

   Abstract/FREE Full Text
10. 10.↵
    2. Kwon DH,
    3. Kim JM,
    4. Oh SH, et al

    . Seven-Tesla magnetic resonance images of the substantia nigra in Parkinson disease. Ann Neurol 2012;71:267–77 doi:10.1002/ana.22592 pmid:22367998

    CrossRefPubMed
11. 11.↵
    2. Schwarz ST,
    3. Afzal M,
    4. Morgan PS, et al

    . The “swallow tail” appearance of the healthy nigrosome: a new accurate test of Parkinson's disease—a case-control and retrospective cross-sectional MRI study at 3T. PLoS One 2014;9:e93814 doi:10.1371/journal.pone.0093814 pmid:24710392

    CrossRefPubMed
12. 12.↵
    2. Bae YJ,
    3. Kim JM,
    4. Kim E, et al

    . Loss of nigral hyperintensity on 3 Tesla MRI of parkinsonism: comparison with (123) I-FP-CIT SPECT. Mov Disord 2016;31:684–92 doi:10.1002/mds.26584 pmid:26990970

    CrossRefPubMed
13. 13.↵
    2. Kim JM,
    3. Jeong HJ,
    4. Bae YJ, et al

    . Loss of substantia nigra hyperintensity on 7 Tesla MRI of Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Parkinsonism Relat Disord 2016;26:47–54 doi:10.1016/j.parkreldis.2016.01.023 pmid:26951846

    CrossRefPubMed
14. 14.↵
    2. Blazejewska AI,
    3. Schwarz ST,
    4. Pitiot A, et al

    . Visualization of nigrosome 1 and its loss in PD: pathoanatomical correlation and in vivo 7 T MRI. Neurology 2013;81:534–40 doi:10.1212/WNL.0b013e31829e6fd2 pmid:23843466

    Abstract/FREE Full Text
15. 15.↵
    2. Fearnley JM,
    3. Lees AJ

    . Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114(pt 5):2283–301 doi:10.1093/brain/114.5.2283 pmid:1933245

    CrossRefPubMedWeb of Science
16. 16.↵
    2. Damier P,
    3. Hirsch EC,
    4. Agid Y, et al

    . The substantia nigra of the human brain, I: nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain 1999;122(pt 8):1421–36 doi:10.1093/brain/122.8.1421 pmid:10430829

    CrossRefPubMedWeb of Science
17. 17.↵
    2. Damier P,
    3. Hirsch EC,
    4. Agid Y, et al

    . The substantia nigra of the human brain, II: patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999;122(pt 8):1437–48 doi:10.1093/brain/122.8.1437 pmid:10430830

    CrossRefPubMedWeb of Science
18. 18.↵
    2. Haller S,
    3. Fällmar D,
    4. Larsson EM

    . Susceptibility weighted imaging in dementia with Lewy bodies: will it resolve the blind spot of MRI? Neuroradiology 2016;58:217–18 doi:10.1007/s00234-015-1605-6 pmid:26458890

    CrossRefPubMed
19. 19.↵
    2. Shams S,
    3. Martola J,
    4. Granberg T, et al

    . Cerebral microbleeds: different prevalence, topography, and risk factors depending on dementia diagnosis—the Karolinska Imaging Dementia Study. AJNR Am J Neuroradiol 2015;36:661–66 doi:10.3174/ajnr.A4176 pmid:25523590

    Abstract/FREE Full Text
20. 20.↵
    2. Shams S,
    3. Granberg T,
    4. Martola J, et al

    . Cerebrospinal fluid profiles with increasing number of cerebral microbleeds in a continuum of cognitive impairment. J Cereb Blood Flow Metab 2016;36:621–28 doi:10.1177/0271678X15606141 pmid:26661151

    CrossRefPubMed
21. 21.↵
    2. Benjamini Y,
    3. Hochberg Y

    . Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995;57:289–300
22. 22.↵
    2. Meijer FJ,
    3. Steens SC,
    4. van Rumund A, et al

    . Nigrosome-1 on susceptibility weighted imaging to differentiate Parkinson's disease from atypical parkinsonism: an in vivo and ex vivo pilot study. Pol J Radiol 2016;81:363–69 doi:10.12659/PJR.897090 pmid:27559425

    CrossRefPubMed
23. 23.↵
    2. Kamagata K,
    3. Nakatsuka T,
    4. Sakakibara R, et al

    . Diagnostic imaging of dementia with Lewy bodies by susceptibility-weighted imaging of nigrosomes versus striatal dopamine transporter single-photon emission computed tomography: a retrospective observational study. Neuroradiology 2017;59:89–98 doi:10.1007/s00234-016-1773-z pmid:28035426

    CrossRefPubMed
24. 24.↵
    2. Zecca L,
    3. Casella L,
    4. Albertini A, et al

    . Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease. J Neurochem 2008;106:1866–75 pmid:18624918

    PubMedWeb of Science
25. 25.↵
    2. Beauchet O,
    3. Allali G,
    4. Berrut G, et al

    . Gait analysis in demented subjects: interests and perspectives. Neuropsychiatr Dis Treat 2008;4:155–60 pmid:18728766

    PubMed
26. 26.↵
    2. Cosottini M,
    3. Frosini D,
    4. Pesaresi I, et al

    . Comparison of 3T and 7T susceptibility-weighted angiography of the substantia nigra in diagnosing Parkinson disease. AJNR Am J Neuroradiol 2015;36:461–66 doi:10.3174/ajnr.A4158 pmid:25376811

    Abstract/FREE Full Text